Compound News and Research

RSS

Longer looks: Turning doctors' views of alternative therapies; a male birth control pill; teenagers and tanning beds

Medicine has long decried acupuncture, homeopathy, and the like as dangerous nonsense that preys on the gullible. Again and again, carefully controlled studies have shown alternative medicine to work no better than a placebo. But now many doctors admit that alternative medicine often seems to do a better job of making patients well, and at a much lower cost, than mainstream care — and they're trying to learn from it.

18 Jun 2011

Niclosamide drug effective against colon cancer metastasis

A compound that for about 60 years has been used as a drug against tapeworm infection is also apparently effective against colon cancer metastasis, as studies using mice have now shown.

18 Jun 2011

Sunshine enters Adva-27a cancer research and development agreement with The Jewish General Hospital

Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Jewish General Hospital, one of McGill University's Hospital Centers, to conduct the necessary research and development to advance Sunshine's lead compound, Adva-27a, through the various stages of preclinical studies and Phase I clinical trials.

17 Jun 2011

Precisely mapped allosteric binding site will facilitate design of drugs with minimal side effects

Structural biologists at Cold Spring Harbor Laboratory (CSHL) have obtained a precise molecular map of the binding site for an allosteric inhibitor in a subtype of the NMDA (N-methyl-D-aspartate) receptor, which is commonly expressed in brain cells.

17 Jun 2011

Innovative adult stem cell approach could help eliminate obesity

Innovative adult stem cell research by scientists at The University of Texas Health Science Center at Houston could aid efforts to apply the brakes to stem cells that produce the type of fat ringing the waists of millions. Research appeared today online ahead of the print issue of Cell Stem Cell.

17 Jun 2011

Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists

Today, Zealand Pharma, a Copenhagen based biopharmaceutical company, and Boehringer Ingelheim, one of the world's leading pharmaceutical companies, jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.

16 Jun 2011

Ethicon Endo-Surgery introduces ENSEAL G2 Super Jaw advanced bipolar technology

To address surgeons' need for achieving strong vessel seals while remaining gentle on tissue in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces the launch of its innovative ENSEAL® G2 Super Jaw advanced bipolar technology.

15 Jun 2011

Bayer's submission of IND for BAY 94-9343 triggers $2M milestone payment to ImmunoGen

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Bayer HealthCare Pharmaceuticals' submission of an Investigational New Drug (IND) application for the TAP compound, BAY 94-9343, triggers a $2 million milestone payment to ImmunoGen.

15 Jun 2011

China Botanic net sales increase 56.1% to $18.9 million for second quarter 2011

China Botanic Pharmaceutical Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines in China, today announced financial results for the three months ended April 30, 2011.

15 Jun 2011

inVentiv Health acquires i3 CRO

inVentiv Health, Inc., offering best-in-class clinical, consulting and commercial services to the healthcare industry, today announced it has completed the acquisition of i3, a top-tier contract research organization (CRO) to the pharmaceutical, biotech and medical device industries. i3 was previously owned by Ingenix, a UnitedHealth Group company.

13 Jun 2011

Servier, Cortex sign new option agreement for AMPAKINE technology

Cortex Pharmaceuticals, Inc. entered into a new agreement with Servier to sell its remaining rights to the jointly discovered high impact AMPAKINE compound, CX1632.

13 Jun 2011

Ambit Biosciences raises $30 million through Series D-2 equity financing

Ambit Biosciences (Ambit), an emerging biopharmaceutical company engaged in the development of kinase inhibitors for the treatment of cancer and other conditions, today announced that it has completed a Series D-2 round of equity financing, raising $30 million in new capital.

10 Jun 2011

Neoprobe's Lymphoseek Phase 3 trial data presented at SNM annual meeting

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that full results from the NEO3-05 study, demonstrating Lymphoseek met all primary and secondary endpoints in intraoperative lymphatic mapping (ILM) procedures.

10 Jun 2011

FDA grants Fast Track Designation for Emergent BioSolutions' NuThrax vaccine

Emergent BioSolutions Inc. announced today that its investigational anthrax vaccine, NuThrax, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA).

10 Jun 2011

University of Mississippi grants ChromaDex global rights to pterostilbene

ChromaDex Corp. and the University of Mississippi today announced the university has granted the natural products company the exclusive worldwide patent rights to a potential new therapeutic use for pterostilbene (tero-STILL-bean) as an anxiolytic or anti-anxiety agent. ChromaDex' pTeroPure® is an ultra-pure formulation of pterostilbene, a compound found in blueberries and demonstrated to have multiple health benefits.

9 Jun 2011

Isotechnika reports consolidated net loss of $2.9 million for first quarter 2011

Isotechnika Pharma Inc. today announced financial and operating results for the three months ended March 31, 2011.

9 Jun 2011

Integromics launches OmicsHub Proteomics 2.0

Integromics, a market leader in IT solutions provision for life sciences in the field of genomics and proteomics, today announces the availability of OmicsHub(R) Proteomics 2.0, a new version of the OmicsHub product adding several new features to its existing centralized data management and analysis capabilities for mass spectrometry laboratories and core facilities.

8 Jun 2011